Financial Support Announced for UK's Health Industries - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Financial Support Announced for UK's Health Industries

Innovative business and academic projects from across the UK’s health sector will benefit from a new £93.2 million ($123,909,400 dollars) package of support announced by Universities and Science Minister David Willetts.

The investment includes £25.9 million ($34,434,050 dollars) from Round 3 of the Biomedical Catalyst, through which 29 companies and five universities will receive investment. Projects include clinical trials to repurpose a cancer drug that could be used to treat rheumatoid arthritis and an implant to reduce pain and restore mobility to knee cartilage injuries.

As part of the recent Spending Review, it was announced that there will be additional support for the Catalyst. Academic researchers and universities can continue to apply for additional funding through the Technology Strategy Board and Medical Research Council in Round 4 of the Biomedical Catalyst, which is now open.

A new £38 million ($50,521,000 dollars) National Biologics Manufacturing Centre will be based in Darlington. The centre, being funded through investment announced as part of the life sciences strategy, will be a national base for the manufacturing of biological medicines such as antibodies and vaccines.

A further £29.3 million ($38,954,350 dollars) of investment in healthcare innovation has been announced through three Technology Strategy Board-led funding competitions. These will support businesses in areas such as stratified medicine and regenerative medicin.

Source: UK Department for Business Innovation and Skills


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here